A recent study showed that the CHADS2 and CHA2DS2-VASc scores, which were originally formulated for risk assessment of stroke in patients with atrial fibrillation, were good predictors of 5-year outcomes in non-AF patients with AIS. The CHA2DS2-VASc score correlated well with stroke severity in AF patients, and was a multivariate predictor of 90-day stroke outcome, independently of baseline NIHSS values. The aim of the present study was to investigate the association of the CHA2DS2-VASc score with poor short-term functional Loxapine Succinate outcome in patients with AIS, regardless of the heart rhythm, and to examine whether the addition of TnI affects the model discriminatory ability regarding the poor short-term outcome of AIS. We tested the hypothesis that the CHA2DS2VASc score is significantly associated with poor short-term stroke outcome and that adding TnI improves the model predictive ability. In-hospital mortality was defined as death from any cause during the index hospitalization. Chromatin assembly is a critical process related to DNA replication, gene expression and progression through the cell cycle. Specific modifications are associated with certain DNA templatemediated processes. Methylation of histone H3 lysine 9 is one of the most well-studied histone modifications. After the initial identification of SUV39h1 in addition to the highly related SUV39h2 as a H3K9-specific histone methyltransferase, at least three other HMTs, G9a, ESET/SETDB1 and EuHMTase1, have been recognized as HMTs for H3K9 in mammals. These enzymes have different affinities for the un-, mono- or dimethylated states and produce different methylation states. Studies in knockout mice for Suv39h1, 2 and G9a revealed that G9a is mainly responsible for Sertraline hydrochloride monomethylation and dimethylation of H3K9, whereas Suv39h1 and Suv39h2 direct trimethylation of H3K9. Furthermore, 1Me and 2Me on H3K9 primarily reside in euchromatin, while 2Me and 3Me on H3K9 are found within different types of heterochromatin, facultative and constitutive heterochromatin, respectively.